WO2005026209A3 - Monoclonal antibodies against hmgb1 - Google Patents

Monoclonal antibodies against hmgb1 Download PDF

Info

Publication number
WO2005026209A3
WO2005026209A3 PCT/US2004/029527 US2004029527W WO2005026209A3 WO 2005026209 A3 WO2005026209 A3 WO 2005026209A3 US 2004029527 W US2004029527 W US 2004029527W WO 2005026209 A3 WO2005026209 A3 WO 2005026209A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
monoclonal antibodies
antibodies against
hmgb
polypeptide
Prior art date
Application number
PCT/US2004/029527
Other languages
French (fr)
Other versions
WO2005026209A2 (en
Inventor
Walter Newman
Shixin Qin
Theresa O'keefe
Robert Obar
Original Assignee
Critical Therapeutics Inc
Walter Newman
Shixin Qin
Theresa O'keefe
Robert Obar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Therapeutics Inc, Walter Newman, Shixin Qin, Theresa O'keefe, Robert Obar filed Critical Critical Therapeutics Inc
Priority to CA2538763A priority Critical patent/CA2538763C/en
Priority to AU2004272607A priority patent/AU2004272607B2/en
Priority to EP04788671A priority patent/EP1668035A2/en
Priority to JP2006526305A priority patent/JP4792392B2/en
Publication of WO2005026209A2 publication Critical patent/WO2005026209A2/en
Publication of WO2005026209A3 publication Critical patent/WO2005026209A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)

Abstract

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
PCT/US2004/029527 2003-09-11 2004-09-10 Monoclonal antibodies against hmgb1 WO2005026209A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2538763A CA2538763C (en) 2003-09-11 2004-09-10 Monoclonal antibodies against hmgb1
AU2004272607A AU2004272607B2 (en) 2003-09-11 2004-09-10 Monoclonal antibodies against HMGB1
EP04788671A EP1668035A2 (en) 2003-09-11 2004-09-10 Monoclonal antibodies against hmgb1
JP2006526305A JP4792392B2 (en) 2003-09-11 2004-09-10 Monoclonal antibody against HMGB1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50256803P 2003-09-11 2003-09-11
US60/502,568 2003-09-11

Publications (2)

Publication Number Publication Date
WO2005026209A2 WO2005026209A2 (en) 2005-03-24
WO2005026209A3 true WO2005026209A3 (en) 2005-09-15

Family

ID=34312406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029527 WO2005026209A2 (en) 2003-09-11 2004-09-10 Monoclonal antibodies against hmgb1

Country Status (7)

Country Link
US (4) US7288250B2 (en)
EP (1) EP1668035A2 (en)
JP (2) JP4792392B2 (en)
CN (1) CN1878793A (en)
AU (1) AU2004272607B2 (en)
CA (2) CA2538763C (en)
WO (1) WO2005026209A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) † 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1668035A2 (en) * 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
EP1717250A4 (en) * 2004-02-20 2008-10-01 Immuno Biological Lab Co Ltd Monoclonal antibody and use thereof
EP1768698A4 (en) * 2004-06-17 2009-01-28 Medimmune Inc Immunogenic compositions comprising hmgb1 polypeptides
US7470521B2 (en) 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
AU2005333602B2 (en) * 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
EP1819731A4 (en) * 2004-12-08 2013-02-13 Immunomedics Inc Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US20100040607A1 (en) * 2005-05-13 2010-02-18 Tracey Kevin J Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases
WO2006138429A2 (en) * 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
US20100040608A1 (en) * 2005-07-18 2010-02-18 Marie Wahren-Herlenius Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
ES2543341T3 (en) 2005-09-13 2015-08-18 National Research Council Of Canada Methods and compositions to modulate the activity of tumor cells
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
JP3876325B1 (en) * 2005-10-24 2007-01-31 国立大学法人 岡山大学 Cerebral infarction inhibitor
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
JP3882090B1 (en) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 Cerebral vasospasm inhibitor
CN1850863B (en) * 2006-05-23 2012-07-04 中国科学院生物物理研究所 Antibody to self-antigen and/or intergeneric high conservative antigen, and its preparing method
JP4982739B2 (en) * 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 Preventive and therapeutic agent for polyglutamine disease
EP2105447A4 (en) * 2006-12-20 2010-05-05 Shino Test Corp Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
WO2008099920A1 (en) 2007-02-15 2008-08-21 Kyushu University, National University Corporation Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
JP5285437B2 (en) * 2007-02-15 2013-09-11 学校法人福岡大学 Organ transplant rejection inhibitor containing anti-HMGB-1 antibody
CA2722909A1 (en) 2008-04-30 2009-11-05 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
ITMI20080799A1 (en) * 2008-04-30 2009-11-01 Areta Internat S R L MONOCLONAL ANTIBODIES AMTI HMGA1 PROCEDURE FOR THEIR PREPARATION AND THEIR USE FOR THE QUANTITATIVE DETERMINATION OF HMGA1
DK2329266T3 (en) 2008-09-11 2016-07-18 Pasteur Institut MONITORING AND INHIBITING INFECTION WITH HUMAN IMMUNE DEFECT VIRUS BY MODULATING HMGB1-DEPENDENT TRACTOR OF HIV-1 REPLICATION AND PERSISTENCE
CN101891817B (en) * 2009-03-03 2012-11-07 中国科学院生物物理研究所 Monoclonal antibody capable of preventing high mobility group box-1 (HMGB-1) and application thereof
CN101798347B (en) * 2009-03-03 2012-05-30 中国科学院生物物理研究所 Monoclonal antibody for resisting high mobility group protein B1
CN108912228B (en) * 2009-05-08 2022-03-15 瓦西尼斯公司 anti-CD 100 antibodies and methods of use thereof
EP2455469A4 (en) * 2009-07-16 2013-03-13 Nec Software Ltd Nucleic acid molecule capable of binding to hmgb1, and use thereof
JP2011095014A (en) * 2009-10-27 2011-05-12 Canon Inc Immunological measuring method and immunological measuring kit
AU2010312537A1 (en) 2009-10-28 2012-05-17 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
ES2734886T3 (en) 2009-11-24 2019-12-12 Alethia Biotherapeutics Inc Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche Multispecific antibodies, antibody analogs, compositions, and methods
EP2365332B1 (en) 2010-03-10 2013-05-29 Institut Pasteur HMGB1 and anti-HMGB1 antibodies in HIV infected patients especially with neurological disorders
US8999349B2 (en) * 2010-07-27 2015-04-07 The Regents Of The University Of California HMGB1-derived peptides enhance immune response to antigens
CN102375064A (en) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 In-vitro diagnostic kit for detecting HMGA2 (High Mobility Group A) content with enzyme-linked immuno sorbent assay
WO2012074043A1 (en) * 2010-12-03 2012-06-07 国立大学法人 岡山大学 Therapeutic agent for traumatic neurological disorders
US9045534B2 (en) * 2011-04-05 2015-06-02 Dia.Pro Diagnostic Bioprobes S.R.L. HMGB1 specific monoclonal antibodies
PT3358011T (en) * 2011-04-26 2020-04-23 Univ Osaka Peptide for inducing regeneration of tissue and use thereof
US9561274B2 (en) * 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US20140377288A1 (en) * 2011-09-16 2014-12-25 The Board Of Regents Of The University Of Texas System Compositions and methods related to dna damage repair
EA029023B1 (en) 2011-10-11 2018-01-31 Вэксинекс, Инк. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
WO2013091903A1 (en) * 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
CN104159611A (en) 2012-02-22 2014-11-19 阿莱斯亚生物疗法股份有限公司 Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN102924577B (en) * 2012-11-28 2014-03-26 扬州大学 Chicken high mobility group protein B1 (chHMGB1) antigen polypeptide and anti-chHMGB1 monoclonal antibody
SI2949675T1 (en) 2013-01-28 2021-08-31 Evec Inc. Humanized anti-hmgb1 antibody or antigen-binding fragment thereof
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
WO2015161267A2 (en) * 2014-04-18 2015-10-22 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
US11191808B2 (en) * 2014-07-04 2021-12-07 Industry-University Cooperation Foundation Hanyang University Pharmaceutical composition for suppressing cell transplant rejection
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
JP7467027B2 (en) 2016-05-03 2024-04-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Yeast vaccine vectors containing immunostimulatory and antigenic polypeptides and methods of using same
WO2018017797A1 (en) * 2016-07-22 2018-01-25 Georgia State Universtiy Research Foundation Monoclonal antibodies to b virus and their use for identification of b virus specific reactive peptides
US10730937B2 (en) 2016-08-09 2020-08-04 National University Corporation Tokyo Medical And Dental University Antibodies against HMB1, and composition comprising same for treating or preventing alzheimer's disease
CN110022867A (en) * 2016-09-21 2019-07-16 斯蒂芬·H·索恩 High mobility group protein BOX I mutant
WO2018079393A1 (en) * 2016-10-26 2018-05-03 扶桑薬品工業株式会社 Disulfide-type hmgb1-specific antibody, method for measuring disulfide-type hmgb1 and kit for said measurement, and measurement method capable of quantitating all of hmgb1 molecules including reduced hmgb1, disulfide-type hmgb1 and thrombin-cleavable hmgb1 and kit for said measurement
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
CN109957015A (en) * 2019-04-01 2019-07-02 中国人民解放军海军军医大学国家肝癌科学中心 A kind of preparation method and applications of HMGB1 blocking antibody
EP3875118A4 (en) * 2019-12-18 2022-04-27 National University Corporation Okayama University Use of antibody-drug conjugates and antibodies for drug delivery
EP4126245A2 (en) * 2020-03-31 2023-02-08 Fred Hutchinson Cancer Center Anti-cd33 antibodies and uses thereof
WO2021222944A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
EP4146706A1 (en) 2020-05-04 2023-03-15 The Regents of the University of California Inhibiting anti-enpp1 antibodies
US20230295277A1 (en) * 2020-07-13 2023-09-21 University Of Southern California Universal car-nk cell targeting various epitopes of hiv-1 gp160
CN113151186B (en) * 2021-02-04 2022-02-18 上海交通大学 Monoclonal antibody of anti-human CD271 and application
KR20240004764A (en) 2021-04-30 2024-01-11 칼리버 임뮤노쎄라퓨틱스, 인크. Oncolytic viruses for modified MHC expression
CN113203857B (en) * 2021-05-06 2021-12-31 上海奕检医学检验实验室有限公司 Tumor diagnosis kit
WO2023137291A1 (en) * 2022-01-11 2023-07-20 Board Of Regents, The University Of Texas System Anti-cd94 antibody and chimeric antigen receptor and methods of use thereof
KR20230139195A (en) * 2022-03-25 2023-10-05 부산대학교 산학협력단 Novel HMGB1-Derived Peptide and Uses Thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074337A1 (en) * 2001-03-16 2002-09-26 Bio3 Research S.R.L. Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2002092004A2 (en) * 2001-05-15 2002-11-21 North Shore-Long Island Jewish Research Institute Use of hmg fragment as anti-inflammatory agents
US20030143194A1 (en) * 1999-02-11 2003-07-31 North Shore-Long Island Jewish Research Institute Antagonists of HMG1 for treating inflammatory conditions

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468A (en) * 1849-05-22 ruteyen
US4678772A (en) 1983-02-28 1987-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing glycyrrhizin
JPS6032714A (en) 1983-08-01 1985-02-19 Teijin Ltd Stabilized powdery pharmaceutical composition for application to nasal mucous membrane
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
JPS62166897A (en) 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd Monoclonal antibody against intranuclear nonhistone protein
JPS63135351A (en) 1986-11-28 1988-06-07 Sanwa Kagaku Kenkyusho Co Ltd Glycyrrhetic acid derivative, production thereof and antiulcer agent containing said compound as active component
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2998287B2 (en) 1991-03-13 2000-01-11 千寿製薬株式会社 Glycyrrhetinic acid derivatives
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DK1024191T3 (en) * 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
IT1253431B (en) 1991-12-02 1995-08-08 Valetudo S R L PHARMACEUTICAL PREPARATIONS FOR TOPICAL USE FOR THE TREATMENT OF PSORIASIS AND ATOPIC DERMATITIS
IT1254321B (en) 1992-04-10 1995-09-14 Kemiprogress S R L PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CUTANEOUS INFLAMMATIONS AND ORAL MUCOSA.
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
EP0727487A1 (en) 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes
JP3472048B2 (en) 1995-10-09 2003-12-02 鐘淵化学工業株式会社 Diagnostics for autoimmune diseases
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
DE19548122A1 (en) 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nucleic acid sequences of high mobility group protein genes and uses thereof
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
CA2262443A1 (en) * 1996-07-17 1998-01-22 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
JP2002514083A (en) 1997-05-07 2002-05-14 シェーリング コーポレイション Human Toll-like receptor proteins, related reagents and methods
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
IT1291366B1 (en) 1997-05-14 1999-01-07 Angelini Ricerche Spa ANTIVIRAL PHARMACEUTICAL COMPOSITION INCLUDING GLYCYRHIZIC ACID AND AT LEAST ONE PROTEIN WITH ANTIVIRAL ACTIVITY
US20030027260A1 (en) 1997-10-17 2003-02-06 Genentech, Inc. Human Toll homologues
PT1650219E (en) 1997-10-17 2008-03-31 Genentech Inc Human toll homologues
ES2137125B1 (en) 1997-11-18 2000-08-16 Vinyals S A Lab Dr THE USE OF THE ZINC SALT OF THE GLICIRRETIC ACID IN PREPARATIONS AGAINST ACNE AND THE COMPOSITIONS CONTAINING SUCH SALT.
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
IT1299583B1 (en) 1998-05-19 2000-03-16 Vander Way Limited USE OF HMG-I PROTEIN FOR THE PREPARATION OF MEDICATIONS WITH CYTOTOXIC ACTIVITY
AU765719B2 (en) 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
TWI221082B (en) 1999-04-14 2004-09-21 Sumitomo Chemical Co Pesticidal compositions
AU5320700A (en) 1999-06-04 2000-12-28 Millennium Pharmaceuticals, Inc. Novel toll molecules and uses therefor
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US7572466B1 (en) * 1999-10-13 2009-08-11 Health Research, Inc. Oral immunology using plant product containing a non-enteric pathogen antigen
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001072993A1 (en) 2000-03-31 2001-10-04 Mochida Pharmaceutical Co., Ltd. Tlr/cd14 binding inhibitor
AU6488901A (en) 2000-05-25 2001-12-03 Schering Corp Human receptor proteins; related reagents and methods
GB0015325D0 (en) 2000-06-22 2000-08-16 Danionics As Electrochemical cells
MXPA03007878A (en) 2001-03-02 2004-07-08 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists.
EP1387680A4 (en) 2001-03-05 2010-01-13 Transtech Pharma Inc Benzimidazole derivatives as therapeutic agents
JP2005500254A (en) 2001-03-05 2005-01-06 トランス　テック　ファーマ，インコーポレイテッド Carboxamide derivatives as therapeutic factors
JP2004528307A (en) 2001-03-15 2004-09-16 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Use of pyruvate and / or derivatives thereof for the treatment of inflammatory conditions mediated by cytokines
CA2446458A1 (en) 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
WO2002089743A2 (en) 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4823465B2 (en) 2001-07-13 2011-11-24 株式会社シノテスト Antibody specifically binding to human HMG-1 and method and reagent for immunoassay of human HMG-1 using this antibody
US20030032674A1 (en) 2001-08-13 2003-02-13 Hwang Daniel H. Use of unsaturated fatty acids to treat severe inflammatory diseases
CN1575184A (en) 2001-09-07 2005-02-02 波士顿大学理事会 Method and composition for treating immune complex associated disorders
JP2003088388A (en) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk NEW FULL-LENGTH cDNA
EP1293566A1 (en) * 2001-09-17 2003-03-19 Societe Des Produits Nestle S.A. A soluble toll-like receptor
WO2003057715A2 (en) * 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
ES2373875T3 (en) 2002-03-05 2012-02-09 Transtech Pharma, Inc. DERIVATIVES OF AZOL MONO AND BICYCLES THAT INHIBIT THE INTERACTION OF LIGANDOS WITH RAGE.
RU2005102593A (en) 2002-07-03 2005-10-10 Фондационе Чентро Сан Раффаэле Дель Монте Табор (It) APPLICATION OF HMGB1 IN TREATMENT OF TISSUE DAMAGE AND / OR TO PROMOTE TISSUE RECOVERY
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
AU2003295653B2 (en) 2002-11-20 2007-08-16 The Feinstein Institute Of Medical Research Use of HMGB polypeptides for increasing immune responses
US20040141948A1 (en) * 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1668035A2 (en) * 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
US7807696B2 (en) 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
EP1768698A4 (en) 2004-06-17 2009-01-28 Medimmune Inc Immunogenic compositions comprising hmgb1 polypeptides
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US20090062187A1 (en) * 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
WO2006024547A2 (en) 2004-09-03 2006-03-09 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
AU2005333602B2 (en) * 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US8129130B2 (en) * 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
US20100040608A1 (en) * 2005-07-18 2010-02-18 Marie Wahren-Herlenius Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
AU2006312847A1 (en) 2005-11-09 2007-05-18 Pharmexa A/S Therapeutic vaccines targeting HMGB1
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
ES2902063T3 (en) * 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Interleukin-13 binding proteins
US8173405B2 (en) 2006-12-13 2012-05-08 William Marsh Rice University Nerolidol, terpene, and terpene deriviative synthesis
WO2008154638A2 (en) * 2007-06-12 2008-12-18 Board Of Regents, The University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143194A1 (en) * 1999-02-11 2003-07-31 North Shore-Long Island Jewish Research Institute Antagonists of HMG1 for treating inflammatory conditions
WO2002074337A1 (en) * 2001-03-16 2002-09-26 Bio3 Research S.R.L. Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2002092004A2 (en) * 2001-05-15 2002-11-21 North Shore-Long Island Jewish Research Institute Use of hmg fragment as anti-inflammatory agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUSTIN M ET AL: "ANTIGENIC DETERMINANTS OF HIGH MOBILITY GROUP CHROMOSOMAL PROTEINS 1 AND 2", BIOCHEMISTRY, vol. 21, no. 26, 1982, pages 6773 - 6777, XP001205691, ISSN: 0006-2960 *
CZURA CHRISTOPHER J ET AL: "High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.", JOURNAL OF INFECTIOUS DISEASES, vol. 187, no. Supplement 2, 15 June 2003 (2003-06-15), pages S391 - S396, XP009046409, ISSN: 0022-1899 *
OZAKI S ET AL: "Epitope mapping of autoantibodies to high mobility group (HMG) proteins HMG1 and HMG2", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 120, no. Suppl. 1, May 2000 (2000-05-01), & 9TH INTERNATIONAL ANCA WORKSHOP ON CLINICAL AND EXPERIMENTAL IMMUNOLOGY; GRONINGEN, NETHERLANDS; APRIL 12-15, 2000, pages 53, XP009046406, ISSN: 0009-9104 *
REEVES R: "Molecular biology of HMGA proteins: hubs of nuclear function", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 277, no. 1-2, 17 October 2001 (2001-10-17), pages 63 - 81, XP004311082, ISSN: 0378-1119 *
YAMADA SHINGO ET AL: "High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2.", CLINICAL CHEMISTRY, vol. 49, no. 9, September 2003 (2003-09-01), pages 1535 - 1537, XP001205689, ISSN: 0009-9147 *

Also Published As

Publication number Publication date
CA2882022A1 (en) 2005-03-24
JP4792392B2 (en) 2011-10-12
EP1668035A2 (en) 2006-06-14
US20050152903A1 (en) 2005-07-14
US7288250B2 (en) 2007-10-30
JP2011241219A (en) 2011-12-01
US20110217292A1 (en) 2011-09-08
US7632500B2 (en) 2009-12-15
AU2004272607B2 (en) 2008-11-06
CA2538763C (en) 2015-05-05
CN1878793A (en) 2006-12-13
CA2538763A1 (en) 2005-03-24
AU2004272607A1 (en) 2005-03-24
JP5513441B2 (en) 2014-06-04
US20090148453A1 (en) 2009-06-11
US20080113385A1 (en) 2008-05-15
US8846047B2 (en) 2014-09-30
WO2005026209A2 (en) 2005-03-24
JP2007527406A (en) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
ATE373719T1 (en) HUMANIZED ANTIBODIES AGAINST CCR2 AND METHOD OF USE THEREOF
RS20050834A (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
TW200510459A (en) RG1 antibodies and uses thereof
CR20130154A (en) PROTEINS OF THE UNION TO IL-12 / P40 (DIVISIONAL EXP. 9599)
DE602006013029D1 (en) ANTI-EGFR ANTIBODY
EP1139101A3 (en) Immunoassay for c-reactive protein
RS52769B (en) Compositions and methods for increasing bone mineralization
WO2005047860A3 (en) Antibodies to alpha-synuclein
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
WO2005114218B1 (en) Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
WO2006091421A3 (en) Peptides for detection of antibody to ehrlichia ewingii
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2006091824A3 (en) Peptides for detection of antibody to porcine reproductive respiratory syndrome virus
EP2295465A3 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
RS54056B1 (en) Anti-cd38 human antibodies and uses therefor
UA96122C2 (en) Anti-il-22ra antibody or antigen binding fragment thereof and methods of use
WO2006138429A3 (en) Antibodies against hmgb1 and fragments thereof
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
MX2008000282A (en) Monoclonal antibodies, hybridoma cell lines, methods and kits for detecting phytase.
WO2008025964A3 (en) Antibodies to an epitope of agr2. assays and hybridomas
ATE517340T1 (en) SETS OF DIGITAL ANTIBODIES DIRECTED AGAINST SHORT EPITOPES AND METHODS USING THEM
WO2005072126A3 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
WO2005020891A3 (en) Monoclonal antibodies against ricin toxin and methods of making and using thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480033217.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004272607

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1254/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006526305

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2538763

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004272607

Country of ref document: AU

Date of ref document: 20040910

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004272607

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004788671

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004788671

Country of ref document: EP